Carlo De Cicco Nardone

Carlo De Cicco Nardone

Auto-generated profile, based on publicly available information

Carlo De Cicco Nardone

Department of Obstetrics and Gynecology, 'Campus Bio-Medico' University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Fertility and Sterility
Verified
Journal Article
Open access
KNKelechi E. Nnoaham
Kelechi E. Nnoaham
LHLone Hummelshoj
Lone Hummelshoj
PWPremila Webster
Premila Webster
TDThomas D’hOoghe
Thomas D’hOoghe
FNFiorenzo de Cicco Nardone
Fiorenzo de Cicco Nardone
KZKrina Zondervan
Krina Zondervan
To assess the impact of endometriosis on health-related quality of life (HRQoL) and work productivity. Multicenter cross-sectional study with prospective recruitment. Sixteen clinical centers in ten countries. A total of 1,418 premenopausal women, aged 18-45 years, without a previous surgical diagnosis of endometriosis, having laparoscopy to investigate symptoms or to be sterilized. None. Diagnostic delay, HRQoL, and work productivity. There was a delay of 6.7 years, principally in primary care, between onset of symptoms and a surgical diagnosis of endometriosis, which was longer in centers where women received predominantly state-funded health care (8.3 vs. 5.5 years). Delay was positively associated with the number of pelvic symptoms (chronic pelvic pain, dysmenorrhoea, dyspareunia, and heavy periods) and a higher body mass index. Physical HRQoL was significantly reduced in affected women compared with those with similar symptoms and no endometriosis. Each affected woman lost on average 10.8 hours (SD 12.2) of work weekly, mainly owing to reduced effectiveness while working. Loss of work productivity translated into significant costs per woman/week, from US$4 in Nigeria to US$456 in Italy. Endometriosis impairs HRQoL and work productivity across countries and ethnicities, yet women continue to experience diagnostic delays in primary care. A higher index of suspicion is needed to expedite specialist assessment of symptomatic women. Future research should seek to clarify pain mechanisms in relation to endometriosis severity.

13 October 2010 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
CCC De Cicco
C De Cicco
RCR Corona
R Corona
RSR Schonman
R Schonman
KMK Mailova
K Mailova
AUA Ussia
A Ussia
PKPr Koninckx
Pr Koninckx

25 July 2017 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
GSGiuseppe Scaletta
Giuseppe Scaletta
FPFrancesco Plotti
Francesco Plotti
DLDaniela Luvero
Daniela Luvero
SCStella Capriglione
Stella Capriglione
RMRoberto Montera
Roberto Montera
RARoberto Angioli
Roberto Angioli
Introduction: Ovarian cancer is the leading cause of death from gynecologic cancers, in fact, >80% of cases are diagnosed as advanced-stage disease associated with a high mortality rate (<40% of women cured). A systematic review was performed to estimate the role of HE4 in the diagnosis, prognosis and follow-up of ovarian tumors. Areas covered: A comprehensive search of the literature from January 1952 to August 2016 was conducted using the terms ‘ovarian tumor’ and ‘ovarian cancer’ combined with ‘HE4’ and ‘human epididymis protein 4’. The search identified a total of 259 citations, of which 141 were potentially relevant after initial evaluation. Of these studies, 75 primary studies met the inclusion criteria and were analyzed, with a total of 14,773 patients. Expert commentary: Serum HE4 dosage is a useful preoperative test for predicting the benign or malignant nature of pelvic masses. It seems to have a promising role in the prediction of clinical and surgical outcomes. Moreover, HE4 seems to better predict recurrence in comparison to CA-125.

1 May 2014 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
RARoberto Angioli
Roberto Angioli
CNCarlo De Cicco Nardone
Carlo De Cicco Nardone
FPFrancesco Plotti
Francesco Plotti
ECEster Valentina Cafà
Ester Valentina Cafà
NDNella Dugo
Nella Dugo
Corrado TerranovaCorrado Terranova
Corrado Terranova

1 November 2012 in Gynecologic Oncology
Verified
Journal Article
Closed access
RARoberto Angioli
Roberto Angioli
FPFrancesco Plotti
Francesco Plotti
RMRoberto Montera
Roberto Montera
AAAlessia Aloisi
Alessia Aloisi
DLDaniela Luvero
Daniela Luvero
PBPierluigi Benedetti-Panici
Pierluigi Benedetti-Panici

4 March 2018 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
PCP. Carfagna
P. Carfagna
CNC. De Cicco Nardone
C. De Cicco Nardone
ANA. De Cicco Nardone
A. De Cicco Nardone
ATA. C. Testa
A. C. Testa
GSG. Scambia
G. Scambia
FNF. De Cicco Nardone
F. De Cicco Nardone